Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.
The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3).
Nagarajan
Srinivasan R
SR
Pfizer Global Research and Development, St. Louis Laboratories, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA. Srinivasan.Nagarajan@Pfizer.com
Lu
Hwang-Fun
HF
Gasiecki
Alan F
AF
Khanna
Ish K
IK
Parikh
Mihir D
MD
Desai
Bipinchandra N
BN
Rogers
Thomas E
TE
Clare
Michael
M
Chen
Barbara B
BB
Russell
Mark A
MA
Keene
Jeffery L
JL
Duffin
Tiffany
T
Engleman
V Wayne
VW
Finn
Mary B
MB
Freeman
Sandra K
SK
Klover
Jon A
JA
Nickols
G Alan
GA
Nickols
Maureen A
MA
Shannon
Kristen E
KE
Steininger
Christina A
CA
Westlin
William F
WF
Westlin
Marisa M
MM
Williams
Melanie L
ML
D000085:Acetates / Q000138:chemical synthesis* / Q000494:pharmacology*; D000818:Animals; D019540:Area Under Curve; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D018360:Crystallography, X-Ray; D015195:Drug Design; D006207:Half-Life; D006801:Humans; D007202:Indicators and Reagents; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D009287:Naphthyridines / Q000138:chemical synthesis* / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013056:Spectrophotometry, Ultraviolet; D013329:Structure-Activity Relationship; D014162:Transfection
C520657:2-(4-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxyphenyl)-cyclopropyl)acetic acid; D000085:Acetates; D007202:Indicators and Reagents; D039302:Integrin alphaVbeta3; D009287:Naphthyridines